CD8A and non-small cell lung carcinoma: This pathway promotes CD8+ T cell infiltration and effective antigen presentation, with lower RGS1 expression linked to reduced PD1 inhibitor efficacy and shorter progression‐free survival in Non‐small cell lung cancer (NSCLC) patients.43